Takeda abandons cooperation with intra cellular $750 million pde1 inhibitor

Source: Takeda and intra cellular signed an agreement of up to $750 million in February 2011 to jointly develop phosphodiesterase 1 (pde1) inhibitors for the treatment of cognitive impairment in schizophrenia Recently, with the consent of both parties, Takeda has terminated this cooperation and returned all rights of iti-214 and related pde1 inhibitors to intra cellular Takeda said it will no longer participate in future development and commercialization activities, and intra cellular said it will continue to promote pde1 alone Clinical development of inhibitors for the treatment of central nervous system, cardiovascular and other diseases Under the terms of the agreement, intracellular has regained global development and commercialization rights for all compounds previously licensed to Takeda Pde1 inhibitor is a unique and effective oral experimental drug candidate It is currently being developed for the treatment of schizophrenia, Alzheimer's disease and other neuropsychiatric disorders and neurological diseases with cognitive impairment In addition, pde1 inhibitors are also expected to be used in the treatment of attention deficit hyperactivity disorder and Parkinson's disease In addition, pde1 inhibitors are highly selective to pde1 family members, and no significant Miss targeting effect on other enzymes, receptors and ion channels has been found.